XtalPi Holdings Ltd
OTC:QNTPF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
XtalPi Holdings Ltd
Revenue
XtalPi Holdings Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XtalPi Holdings Ltd
OTC:QNTPF
|
Revenue
¥802.6m
|
CAGR 3-Years
82%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Revenue
¥45.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Revenue
¥14.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Revenue
¥21.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Revenue
¥6.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Revenue
¥5.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
128%
|
CAGR 10-Years
N/A
|
|
XtalPi Holdings Ltd
Glance View
XtalPi Holdings Ltd. provides drug and material science R&D solutions and services to global conglomerates and companies in the pharmaceutical and material science industries. The company is headquartered in Shenzhen, Guangdong and currently employs 760 full-time employees. The company went IPO on 2024-06-13. The firm mainly operates two businesses. The drug discovery solutions business is engaged in providing modular standalone solutions to or collaborating with a diverse range of biotechnology and pharmaceutical companies and academic institutions for novel drug discovery endeavors. The intelligent automation solutions business is engaged in the provision of solid-state research and development services and automated chemical synthesis services. The firm conducts its business in the domestic and overseas markets.
See Also
What is XtalPi Holdings Ltd's Revenue?
Revenue
802.6m
CNY
Based on the financial report for Dec 31, 2025, XtalPi Holdings Ltd's Revenue amounts to 802.6m CNY.
What is XtalPi Holdings Ltd's Revenue growth rate?
Revenue CAGR 3Y
82%
Over the last year, the Revenue growth was 201%. The average annual Revenue growth rates for XtalPi Holdings Ltd have been 82% over the past three years .
